How have GMTX shares performed in 2024?

Gemini Therapeutics' stock was trading at $57.76 at the start of the year. Since then, GMTX stock has decreased by 47.6% and is now trading at $30.28. View the best growth stocks for 2024 here .

How were Gemini Therapeutics' earnings last quarter?

Gemini Therapeutics, Inc. (NASDAQ:GMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.04.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free GMTX Stock Alerts

$30.02

-0.26 (-0.86%)

(As of 04/18/2024 ET)

Compare

Today's Range: $29.85
▼
$30.38
50-Day Range: $29.50
▼
$75.32
52-Week Range: $1.16
▼
$14.10

Volume: 315,937 shs
Average Volume: 189,291 shs
Market Capitalization: $1.30 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Insider Trades SEC Filings Social Media

Get Gemini Therapeutics alerts:

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

GMTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GMTX Stock News Headlines

April 17, 2024 | seekingalpha.com

Google's public release of Gemini 1.5 should build trust, Deutsche Bank says

February 26, 2024 | washingtonpost.com

Google takes down Gemini AI image generator. Here’s what you need to know.

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

February 26, 2024 | nypost.com

‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiasco

June 24, 2023 | benzinga.com

(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson Fistel

June 1, 2023 | barrons.com

Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation

January 13, 2023 | markets.businessinsider.com

The Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalates

January 1, 2023 | usatoday.com

Gemini Horoscope

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

December 27, 2022 | finance.yahoo.com

Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

October 31, 2022 | finance.yahoo.com

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

September 27, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTX

September 26, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY

September 16, 2022 | markets.businessinsider.com

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZ

September 6, 2022 | markets.businessinsider.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFE

August 25, 2022 | apnews.com

The M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTX

August 24, 2022 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing Investigations

August 12, 2022 | apnews.com

GEMINI THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GMTX and Encourages Investors to Contact the Firm

August 12, 2022 | marketwatch.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. Merger

August 11, 2022 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.

August 11, 2022 | apnews.com

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ

August 11, 2022 | apnews.com

GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders

August 10, 2022 | apnews.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Gemini Therapeutics, Inc. (Nasdaq – GMTX)

August 10, 2022 | finance.yahoo.com

Blood disorder startup goes public by merging with embattled biotech

August 10, 2022 | seekingalpha.com

Gemini stock soars 35% on merger with Disc Medicine in all-stock deal

August 10, 2022 | nasdaq.com

Gemini Therapeutics, Disc Medicine Announce All-stock Merger

August 10, 2022 | finance.yahoo.com

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

See More Headlines

Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GMTX
CUSIP: N/A
CIK: 1816736
Web: www.geminitherapeutics.com
Phone: 415-877-4887
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,870,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.78%
Return on Assets: -35.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 71.49
Quick Ratio: 71.49

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.89 per share
Price / Book: 10.39

Miscellaneous

Outstanding Shares: 43,328,000
Free Float: 37,739,000
Market Cap: $1.30 billion
Optionable: Not Optionable
Beta: -0.12

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Georges Gemayel C.F.A. (Age 62)
Ph.D., Interim Pres & CEO and Exec. Chairperson
Comp: $256.73k
Mr. Brian Piekos (Age 46)
Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer
Comp: $549.73k
Mr. Jason Patrick Meyenburg M.B.A. (Age 44)
M.D., Advisor
Comp: $715.96k
Mr. Patrick Truesdell (Age 41)
VP of Fin. & Controller

Key Competitors

View All Competitors

GMTX Stock Analysis - Frequently Asked Questions

How have GMTX shares performed in 2024?: Gemini Therapeutics' stock was trading at $57.76 at the start of the year. Since then, GMTX stock has decreased by 47.6% and is now trading at $30.28.
View the best growth stocks for 2024 here.
How were Gemini Therapeutics' earnings last quarter?: Gemini Therapeutics, Inc. (NASDAQ:GMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.04.
How do I buy shares of Gemini Therapeutics?: Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

About Gemini Therapeutics Stock (NASDAQ:GMTX)

GMTX Stock Price History

GMTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GMTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info